Patterns of current and lifetime substance use in schizophrenia.
paper
Cited
Public
Unavailable
- Authors
- Fowler, I L; Carr, V J; Carter, N T; Lewin, T J
- Year
- 1998
- Journal
- Schizophrenia bulletin
- PMID
- 9718636
- DOI
- 10.1093/oxfordjournals.schbul.a033339
A structured interview and standardized rating scales were used to assess a sample of 194 outpatients with schizophrenia in a regional Australian mental health service for substance use, abuse, and dependence. Case manager assessments and urine drug screens were also used to determine substance use. Additional measurements included demographic information, history of criminal charges, symptom self-reports, personal hopefulness, and social support. The sample was predominantly male and showed relative instability in accommodations, and almost half had a history of criminal offenses, most frequently drug or alcohol related. The 6-month and lifetime prevalence of substance abuse or dependence was 26.8 and 59.8 percent, respectively, with alcohol, cannabis, and amphetamines being the most commonly abused substances. Current users of alcohol comprised 77.3 percent and current users of other nonprescribed substances (excluding tobacco and caffeine) comprised 29.9 percent of the sample. Rates of tobacco and caffeine consumption were high. There was a moderate degree of concordance between case manager determinations of a substance-use problem and research diagnoses. Subjects with current or lifetime diagnoses of substance abuse/dependence were predominantly young, single males with higher rates of criminal charges; however, there was no evidence of increased rates of suicide attempts, hospital admissions, or daily doses of antipsychotic drugs in these groups compared with subjects with no past or current diagnosis of substance abuse or dependence. Subjects with a current diagnosis of substance use were younger at first treatment and currently more symptomatic than those with no past or current substance use diagnosis. The picture emerging from this study replicates the high rate of substance abuse in persons with schizophrenia reported in North American studies but differs from the latter in finding a slightly different pattern of substances abused (i.e., absence of cocaine), reflecting relative differences in the availability of certain drugs.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A systematic review and meta-analysis of the prevalence of alcohol and other drug use and problematic use among people accessing mental health treatment in Australia. | Marel C et al. | β | 2025 | β |
| The Potential of Hair Matrix for Biomarker Analysis in Schizophrenia. | Rubio-Contreras E et al. | β | 2025 | β |
| Associations of comorbid substance use disorders with clinical outcomes in schizophrenia using electronic health record data. | Patel R et al. | β | 2023 | β |
| Scoping Review of Cannabis-Reduction Psychosocial Interventions and Reasons for Use among Young Adults with Psychosis. | Petros R et al. | β | 2023 | β |
| Alcohol use disorder and its determinant factors among patients with schizophrenia attending treatment at mental specialized hospital, Addis Ababa, Ethiopia: A cross-sectional study. | Tadesse H et al. | β | 2021 | β |
| Personality Traits in Individuals with the Dual Diagnosis of Psychosis and Substance Use Disorders: A Comprehensive Review and Meta-Analysis. | Oh H et al. | β | 2021 | β |
| Predictors of controlled prescription drug non-medical and lifetime use among patients accessing public mental health services in Uganda: a cross-sectional study. | Kamba PF et al. | β | 2021 | β |
| A large-scale genome-wide association study meta-analysis of cannabis use disorder. | Johnson EC et al. | β | 2020 | β |
| Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. | Tao R et al. | β | 2020 | β |
| Substance Use Patterns and Schizophrenia Spectrum Disorders: A Retrospective Study of Inpatients at a Community Teaching Hospital. | Tumenta T et al. | β | 2020 | β |
| The prevalence and clinical correlates of substance use disorders in patients with psychotic disorders from an Upper-Middle-Income Country. | Temmingh HS et al. | β | 2020 | β |
| Epidemiology of hallucinogen use in the U.S. results from the National epidemiologic survey on alcohol and related conditions III. | Shalit N et al. | β | 2019 | β |
| Gene Expression Profiles Associated with Brain Aging are Altered in Schizophrenia. | Sabunciyan S | β | 2019 | β |
| Impact of tobacco, alcohol and cannabis use on treatment outcomes among patients experiencing first episode psychosis: Data from the national RAISE-ETP study. | Oluwoye O et al. | β | 2019 | β |
| Psychoactive substance use among outpatients with severe mental illness: A comparative study. | Sowunmi OA et al. | β | 2019 | β |
| Effectiveness of Integrated Dual Diagnosis Treatment (IDDT) in severe mental illness outpatients with a co-occurring substance use disorder. | Kikkert M et al. | β | 2018 | β |
| Online Communication about Depression and Anxiety among Twitter Users with Schizophrenia: Preliminary Findings to Inform a Digital Phenotype Using Social Media. | Hswen Y et al. | β | 2018 | β |
| Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. | Hunt GE et al. | β | 2018 | β |
| Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. | Temmingh HS et al. | β | 2018 | β |
| The Interrater Reliability of Nursing Outcome Classification (NOC): "Caregiver Performance: Direct Care". | Adistya VK et al. | β | 2018 | β |
| Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders. | Suryadevara U et al. | β | 2017 | β |
| Psychoactive substance use in specialized psychiatric care patients. | Karpov B et al. | β | 2017 | β |
| A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder. | Babatope T et al. | β | 2016 | β |
| Cannabis Use Is Associated With Increased Psychotic Symptoms and Poorer Psychosocial Functioning in First-Episode Psychosis: A Report From the UK National EDEN Study. | Seddon JL et al. | β | 2016 | β |
| Hospitalisation of severely mentally ill patients with and without problematic substance use before and during Assertive Community Treatment: an observational cohort study. | Clausen H et al. | β | 2016 | β |
| Schizophrenia and Suicide Attempts: Findings from a Representative Community-Based Canadian Sample. | Fuller-Thomson E et al. | β | 2016 | β |
| Social Stress and Psychosis Risk: Common Neurochemical Substrates? | Mizrahi R | β | 2016 | β |
| Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis. | Buchy L et al. | β | 2015 | β |
| Factors affecting smoking cessation efforts of people with severe mental illness: a qualitative study. | Rae J et al. | β | 2015 | β |
| Reasons for cannabis use in first-episode psychosis: does strength of endorsement change over 12 months? | Kolliakou A et al. | β | 2015 | β |
| Relationship between cannabis and psychosis: Reasons for use and associated clinical variables. | ManΓ© A et al. | β | 2015 | β |
| "Clozapine makes me quite drowsy, so when I wake up in the morning those first cups of coffee are really handy": an exploratory qualitative study of excessive caffeine consumption among individuals with schizophrenia. | Thompson L et al. | β | 2014 | β |
| Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls. | van der Meer FJ et al. | β | 2014 | β |
| Differences between patients with schizophrenia with and without co-occurring methamphetamine use disorders in a Taiwanese public psychiatric hospital. | Lin CH et al. | β | 2014 | β |
| Prevalence and socio-demographic risk factors associated with psychoactive substance use in psychiatric out-patients of a tertiary hospital in Nigeria. | Okpataku CI et al. | β | 2014 | β |
| Psychiatric correlates of past incarceration in the national co-morbidity study replication. | Greenberg GA et al. | β | 2014 | β |
| Schizophrenia and cancer: is angiogenesis a missed link? | Lopes R et al. | β | 2014 | β |
| Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. | Mizrahi R et al. | β | 2014 | β |
| Substance use disorders in men presenting to a psychosexual clinic. | Rajkumar RP | β | 2014 | β |
| Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. | Large M et al. | β | 2014 | β |
| Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors. | Bahorik AL et al. | β | 2014 | β |
| A case-linkage study of crime victimisation in schizophrenia-spectrum disorders over a period of deinstitutionalisation. | Short TB et al. | β | 2013 | β |
| Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. | Thoma P et al. | β | 2013 | β |
| Does substance use disorder affect clinical expression in first-hospitalization patients with schizophrenia? Analysis of a prospective cohort. | Picci RL et al. | β | 2013 | β |
| Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis. | Gupta P et al. | β | 2013 | β |
| Perceived risk associated with tobacco, alcohol and cannabis use among people with and without psychotic disorders. | Thornton LK et al. | β | 2013 | β |
| Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment. | Lecomte T et al. | β | 2013 | β |
| Reflections of young people who have had a first episode of psychosis: what attracted them to use alcohol and illicit drugs? | Archie S et al. | β | 2013 | β |
| Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia. | Koola MM et al. | β | 2013 | β |
| Treatment of co-occurring psychotic and substance use disorders. | Mueser KT et al. | β | 2013 | β |
| Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. | Koola MM et al. | β | 2012 | β |
| An evaluation of a pilot capacity building initiative for smoking cessation in social and community services: the Smoking Care project. | O'Brien J et al. | β | 2012 | β |
| Assessing illicit drug use among adults with schizophrenia. | Van Dorn RA et al. | β | 2012 | β |
| Attitudes and perceptions towards substances among people with mental disorders: a systematic review. | Thornton LK et al. | β | 2012 | β |
| Detecting psychotic symptoms in Indigenous populations: a review of available assessment tools. | Demarchi C et al. | β | 2012 | β |
| Determinants, self-management strategies and interventions for hope in people with mental disorders: systematic search and narrative review. | Schrank B et al. | β | 2012 | β |
| Does giving up substance use work for patients with psychosis? A systematic meta-analysis. | Mullin K et al. | β | 2012 | β |
| Excessive discounting of delayed reinforcers as a trans-disease process contributing to addiction and other disease-related vulnerabilities: emerging evidence. | Bickel WK et al. | β | 2012 | β |
| Illicit drug use in heavy smokers with and without schizophrenia. | Mackowick KM et al. | β | 2012 | β |
| Meta-analysis of self-reported substance use compared with laboratory substance assay in general adult mental health settings. | Large MM et al. | β | 2012 | β |
| Oxidative Stress-Induced Response of Some Endogenous Antioxidants in Schizophrenia. | Dadheech G et al. | β | 2012 | β |
| Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. | Kelly DL et al. | β | 2012 | β |
| Reasons for substance use among people with mental disorders. | Thornton LK et al. | β | 2012 | β |
| Significant relationship between lifetime alcohol use disorders and suicide attempts in an Australian schizophrenia sample. | McLean D et al. | β | 2012 | β |
| The impact of alcohol and illicit drugs on people with psychosis: the second Australian National Survey of Psychosis. | Moore E et al. | β | 2012 | β |
| The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC). | CarrΓ G et al. | β | 2012 | β |
| The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use. | Koola MM et al. | β | 2012 | β |
| A cross-sectional study of patients with and without substance use disorders in Community Mental Health Centres. | WΓΌsthoff LE et al. | β | 2011 | β |
| Cannabis use and sensorimotor gating in patients with schizophrenia and healthy controls. | Scholes-Balog KE et al. | β | 2011 | β |
| Criminal justice system involvement among people with schizophrenia. | Greenberg G et al. | β | 2011 | β |
| Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. | De Hert M et al. | β | 2011 | β |
| Identifying co-occurring substance use disorders in community mental health centres. Tailored approaches are needed. | WΓΌsthoff LE et al. | β | 2011 | β |
| Is DNA methylation responsible for immune system dysfunction in schizophrenia? | Khojasteh-Fard M et al. | β | 2011 | β |
| Substance use disorder and schizophrenia: prevalence and sociodemographic characteristics in the Latin American population. | JimΓ©nez-Castro L et al. | β | 2011 | β |
| Treatment outcomes of an integrated residential programme for patients with schizophrenia and substance use disorder. | Morrens M et al. | β | 2011 | β |
| Variance of gene expression identifies altered network constraints in neurological disease. | Mar JC et al. | β | 2011 | β |
| Why do patients with psychosis use cannabis and are they ready to change their use? | Kolliakou A et al. | β | 2011 | β |
| How is substance use linked to psychosis? A study of the course and patterns of substance dependence in psychosis. | Saddichha S et al. | β | 2010 | β |
| Implicit and explicit affective associations towards cannabis use in patients with recent-onset schizophrenia and healthy controls. | Dekker N et al. | β | 2010 | β |
| Perceived reasons for and consequences of substance abuse among patients with psychosis. | Saddichha S et al. | β | 2010 | β |
| [Prevalence of psychosis/substance abuse comorbidity. Clinical-epidemiological findings from different treatment settings in a large German city]. | Schnell T et al. | β | 2010 | β |
| Providing nicotine dependence treatment to psychiatric inpatients: the views of Australian nurse managers. | Wye P et al. | β | 2010 | β |
| Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. | Koskinen J et al. | β | 2010 | β |
| Substance use disorder comorbidity with schizophrenia in families of Mexican and Central American ancestry. | JimΓ©nez-Castro L et al. | β | 2010 | β |
| Total smoking bans in psychiatric inpatient services: a survey of perceived benefits, barriers and support among staff. | Wye P et al. | β | 2010 | β |
| [Cannabis and psychosis: search of a causal link through a critical and systematic review]. | Le Bec PY et al. | β | 2009 | β |
| Cognitive impairment in dual diagnosis inpatients with schizophrenia and alcohol use disorder. | Manning V et al. | β | 2009 | β |
| Development and validation of a scale for assessing reasons for substance use in schizophrenia: the ReSUS scale. | Gregg L et al. | β | 2009 | β |
| Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. | van Rossum I et al. | β | 2009 | β |
| Drug and alcohol education for consumer workers and caregivers: a pilot project assessing attitudes toward persons with mental illness and problematic substance use. | Cleary M et al. | β | 2009 | β |
| Dual diagnosis and psychosocial interventions--introduction and commentary. | Thylstrup B et al. | β | 2009 | β |
| Dual diagnosis in a Dublin tertiary addiction centre - A cross-sectional study. | Iro C et al. | β | 2009 | β |
| Effects of Ξ-THC on Working Memory: Implications for Schizophrenia? | Vadhan NP et al. | β | 2009 | β |
| [Is cannabis a vulnerability factor in schizophrenic disorders]. | Laqueille X | β | 2009 | β |
| Prevalence of alcohol use disorders in schizophrenia--a systematic review and meta-analysis. | Koskinen J et al. | β | 2009 | β |
| Psychosocial treatments for people with co-occurring severe mental illness and substance misuse: systematic review. | Cleary M et al. | β | 2009 | β |
| Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. | Horsfall J et al. | β | 2009 | β |
| Schizophrenia: genetics, prevention and rehabilitation. | Olgiati P et al. | β | 2009 | β |
| Smoking restrictions and treatment for smoking: policies and procedures in psychiatric inpatient units in Australia. | Wye PM et al. | β | 2009 | β |
| Substance abuse, temperament and suicide risk: evidence from a case-control study. | Pompili M et al. | β | 2009 | β |
| Substance use disorders among psychotic patients admitted to inpatient psychiatric care. | Helseth V et al. | β | 2009 | β |
| Substance use disorders in schizophrenia--clinical implications of comorbidity. | Volkow ND | β | 2009 | β |
| Substance use in severe mental illness: self-medication and vulnerability factors. | Bizzarri JV et al. | β | 2009 | β |
| The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study. | Gjerden P et al. | β | 2009 | β |
| Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review. | CarrΓ G et al. | β | 2009 | β |
| Volume and neuron number of the lateral geniculate nucleus in schizophrenia and mood disorders. | Dorph-Petersen KA et al. | β | 2009 | β |
| Cannabis, cannabinoids and schizophrenia: integration of the evidence. | Cohen M et al. | β | 2008 | β |
| Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. | van Nimwegen LJ et al. | β | 2008 | β |
| [Induced psychiatric and somatic disorders to cannabis]. | Laqueille X et al. | β | 2008 | β |
| Motives for substance use among young people seeking mental health treatment. | Hides L et al. | β | 2008 | β |
| Reasons for cannabis use: patients with schizophrenia versus matched healthy controls. | Schaub M et al. | β | 2008 | β |
| Reduced tumor growth in a mouse model of schizophrenia, lacking the dopamine transporter. | Asada M et al. | β | 2008 | β |
| Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. | Liu CM et al. | β | 2007 | β |
| Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? | Solowij N et al. | β | 2007 | β |
| Characteristics of smokers with a psychotic disorder and implications for smoking interventions. | Baker A et al. | β | 2007 | β |
| Comparison of self-reports and biological measures for alcohol, tobacco, and illicit drugs consumption in psychiatric inpatients. | de Beaurepaire R et al. | β | 2007 | β |
| Group intervention for coexisting psychosis and substance use disorders in rural Australia: outcomes over 3 years. | Bradley AC et al. | β | 2007 | β |
| Pharmacotherapy for schizophrenia and co-occurring substance use disorders. | Green AI | β | 2007 | β |
| Reasons for increased substance use in psychosis. | Gregg L et al. | β | 2007 | β |
| Risky use and misuse of alcohol, drugs and cigarettes detected by screening questionnaires in a clinical psychosis unit. | Cruce G et al. | β | 2007 | β |
| The amphetamine-induced sensitized state as a model of schizophrenia. | Featherstone RE et al. | β | 2007 | β |
| Typologies of alcohol use disorders among men with schizophrenic disorders. | Eriksson A et al. | β | 2007 | β |
| Clinical experience and management considerations with long-acting risperidone. | Parellada E | β | 2006 | β |
| Comorbid schizophrenia and substance abuse: a review of epidemiology and course. | Westermeyer J | β | 2006 | β |
| Comorbid substance-use in schizophrenia: relation to positive and negative symptoms. | Talamo A et al. | β | 2006 | β |
| Conduct disorder and antisocial personality disorder in persons with severe psychiatric and substance use disorders. | Mueser KT et al. | β | 2006 | β |
| Prevalence of substance use in a Swiss psychiatric hospital: interview reports and urine screening. | Bonsack C et al. | β | 2006 | β |
| Reasons for cannabis use in psychosis. | Schofield D et al. | β | 2006 | β |
| Schizotypy, marijuana, and differential item functioning. | Earleywine M | β | 2006 | β |
| Substance abuse amplifies the risk for violence in schizophrenia spectrum disorder. | Erkiran M et al. | β | 2006 | β |
| The long-term level of functioning in patients admitted for psychotic disorders with and without substance abuse. | MΓΈller T et al. | β | 2006 | β |
| The long-term relationships between the motivation for change and alcohol use severity among patients with severe and persistent mental illness. | Zhang AY et al. | β | 2006 | β |
| Validity of the CAGE questionnaire in schizophrenic patients with alcohol abuse and dependence. | Dervaux A et al. | β | 2006 | β |
| Where there's smoke, there's fire: high prevalence of smoking among some sub-populations and recommendations for intervention. | Baker A et al. | β | 2006 | β |
| Adolescence, schizophrenia and drug abuse: a window of vulnerability. | van Nimwegen L et al. | β | 2005 | β |
| A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. | de Leon J et al. | β | 2005 | β |
| Cannabis use and misuse prevalence among people with psychosis. | Green B et al. | β | 2005 | β |
| Cannabis use and outcome of recent onset psychosis. | Grech A et al. | β | 2005 | β |
| Cannabis use predicts future psychotic symptoms, and vice versa. | Ferdinand RF et al. | β | 2005 | β |
| Cognition in schizophrenia: impairments, determinants, and functional importance. | Bowie CR et al. | β | 2005 | β |
| Comorbidity: cannabis and complexity. | Raphael B et al. | β | 2005 | β |
| Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies. | Baker A et al. | β | 2005 | β |
| Criminality in men with major mental disorder with and without comorbid substance abuse. | Modestin J et al. | β | 2005 | β |
| Deletion of the alpha7 nicotinic receptor subunit gene results in increased sensitivity to several behavioral effects produced by alcohol. | Bowers BJ et al. | β | 2005 | β |
| Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. | D'Souza DC et al. | β | 2005 | β |
| Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? | Roth RM et al. | β | 2005 | β |
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. | Falkai P et al. | β | 2005 | β |
| Balance and gait deficits in schizophrenia compounded by the comorbidity of alcoholism. | Sullivan EV et al. | β | 2004 | β |
| Cannabis and psychopathology : update 2004. | Grover S et al. | β | 2004 | β |
| Cannabis-associated psychosis: current status of research. | Leweke FM et al. | β | 2004 | β |
| Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. | Kavanagh DJ et al. | β | 2004 | β |
| Demographic and clinical correlates of substance abuse comorbidity in schizophrenia. | Aich TK et al. | β | 2004 | β |
| Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. | Margolese HC et al. | β | 2004 | β |
| Potential sampling and recruitment source impacts in schizophrenia research. | Loughland CM et al. | β | 2004 | β |
| Reasons for cannabis use in men with and without psychosis. | Green B et al. | β | 2004 | β |
| Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states'. | Mason O et al. | β | 2004 | β |
| Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types. | Dorph-Petersen KA et al. | β | 2004 | β |
| Suicide attempts in an African schizophrenia population: an assessment of demographic risk factors. | Niehaus DJ et al. | β | 2004 | β |
| Symptoms and lifetime treatment experiences in psychotic patients with and without substance abuse. | MΓΈller T et al. | β | 2004 | β |
| A comparison of schizophrenic patients with or without coexisting substance use disorder. | Farris C et al. | β | 2003 | β |
| A comparison of the patterns of drug use among patients with and without severe mental illness. | Gandhi DH et al. | β | 2003 | β |
| Alcohol, nicotine, caffeine, and mental disorders. | Crocq MA | β | 2003 | β |
| Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. | Carey KB et al. | β | 2003 | β |
| Testing hypotheses about the relationship between cannabis use and psychosis. | Degenhardt L et al. | β | 2003 | β |
| Comparisons between schizophrenia patients recruited from Australian general practices and public mental health services. | Carr VJ et al. | β | 2002 | β |
| Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. | Hausmann A et al. | β | 2002 | β |
| Missed opportunities in the field: caring for clients with co-morbidity problems. | de Crespigny C et al. | β | 2002 | β |
| Motivational interviewing among psychiatric in-patients with substance use disorders. | Baker A et al. | β | 2002 | β |
| Six-month outcomes associated with a brief alcohol intervention for adult in-patients with psychiatric disorders. | Hulse GK et al. | β | 2002 | β |
| The Alcohol Use Disorders Identification Test (AUDIT): a review of recent research. | Reinert DF et al. | β | 2002 | β |
| Work rehabilitation and patterns of substance use among persons with schizophrenia. | Bell M et al. | β | 2002 | β |
| A comparative study on schizophrenic patients with dual diagnosis. | Modestin J et al. | β | 2001 | β |
| An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. | Turenne SD et al. | β | 2001 | β |
| Do alcoholic liver transplantation candidates merit lower medical priority than non-alcoholic candidates? | Martens W | β | 2001 | β |
| Impediments to screening for hazardous alcohol use and dependence in general hospital psychiatric inpatients. | Hulse GK | β | 2001 | β |
| Risk factors for HIV/AIDS and hepatitis C among the chronic mentally ill. | Davidson S et al. | β | 2001 | β |
| Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. | Gut-Fayand A et al. | β | 2001 | β |
| Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. | Cantor-Graae E et al. | β | 2001 | β |
| Addiction and schizophrenia. | Batel P | β | 2000 | β |
| Contrasting views and experiences of health professionals on the management of comorbid substance misuse and mental disorders. | Kavanagh DJ et al. | β | 2000 | β |
| Misuse of anticholinergic drugs by people with serious mental illness. | Buhrich N et al. | β | 2000 | β |
| Relapse prevention in serious mental illness. | Walling DP et al. | β | 2000 | β |
| Substance misuse, psychiatric disorder and violent and disturbed behaviour. | Soyka M | β | 2000 | β |
| Co-occurring severe mental illness and substance use disorders: a review of recent research. | RachBeisel J et al. | β | 1999 | β |
| Experience, knowledge and attitudes of mental health staff regarding patients' problematic drug and alcohol use. | Siegfried N et al. | β | 1999 | β |